Viyash Scientific’s record is built on a foundation of recurring revenue-recognition disputes, a material internal-control breakdown, and an amalgamation that has reshaped its perimeter. The standalone audit opinions have been unqualified every year from FY2020 through FY2026, and a material weakness over revenue was reported in FY2021. Promoter influence runs deep: founder warrants had vesting conditions removed, ESOP exercise prices were cut retrospectively, and public institutions have repeatedly voted against pay and grant resolutions. The balance sheet carries goodwill and subsidiary exposures that have never been impaired outside a single FY2023 Turkey write-down, while loans to subsidiaries carry no repayment schedule.
Key findings
- Revenue recognition is a recurring Key Audit Matter with a history of premature booking
Major- Revenue recognition has been a Key Audit Matter in every annual report from FY21 through FY25. In FY21, management detected that revenue of ₹417.77 crore was recognised earlier than policy allowed and underlying documents were modified. Receivable days rose to 112 days in FY26, up 31% from 85 days in FY25, with the DSRI (receivables/revenue ratio) at 1.31. [SQL] - A material weakness in internal controls over revenue was reported, and the audit trail stays disabled
Major- The internal financial controls opinion was qualified in FY2021 due to a material weakness: the Group lacked appropriate controls for fraud prevention and detection over revenue recognition. The audit trail feature in the accounting software was not enabled for certain changes made using privileged/administrative access rights in every year from FY2024 through FY2026. The standalone audit opinion was unqualified in every year from FY2020 through FY2026. - Goodwill and intangibles keep rising, yet impairment is consistently ruled out outside one FY23 charge
Major- Goodwill impairment has been a Key Audit Matter in every year from FY21 through FY25, with consolidated goodwill at ₹248.79 crore and other intangibles at ₹52.89 crore as at 31 March 2025. No impairment was recorded in FY2026, FY2025, FY2022, or FY2021; the only charge was ₹20.41 crore for the Turkey CGU in FY2023. Standalone investments in subsidiaries rose to ₹647.24 crore and amounts due from subsidiaries to ₹394.94 crore as at 31 March 2025. - Promoter warrants had vesting conditions removed, and public institutions repeatedly dissented on pay and grants
Major- Founder Share Warrants vesting conditions were removed during FY2024-25, making 10,184,856 Performance Linked Warrants and 5,092,428 EHS Linked Warrants exercisable. The ESOP 2022 scheme exercise price was reduced retrospectively from ₹90 to ₹58.5 in FY2023-24. Public institutions cast 63.36% votes against amending the ESOP 2020 plan on 1 September 2023 and 79.39% against granting options to Mr. Rajaram Narayanan on 10 April 2022. - Loans to related parties carry no repayment schedule, and loan receivables were adjusted for equity subscriptions
Major- In FY2026, the Company granted aggregate loans of ₹772.20 million to related parties, with interest added to principal. The schedule of repayment was not stipulated, so the auditor could not comment on regularity. In FY2019, the Company subscribed to a rights issue of Alivira Animal Health Limited for ₹1,547.96 million and adjusted the amount payable against a loan receivable from that subsidiary. - Supplier-financing arrangements shift payables into borrowings, and subsidiary debt is secured by parent pledges
Minor- Consolidated supply-chain financing payables not derecognised rose from ₹2.3 crore in FY25 to ₹12.35 crore in FY26. Consolidated borrowings total ₹436 crore as at 31 March 2026, with 93% sitting in subsidiaries, secured by pledges of subsidiary shares and corporate guarantees from the parent. - The international subsidiary structure is complex, with a history of unaudited entities and a recent large amalgamation
Minor- The Company had 19 subsidiaries as at 31 March 2026, down from 22 in FY22, with three or four unaudited subsidiaries reported each year from FY22 through FY24. A composite Scheme of Arrangement involving eleven entities was sanctioned by NCLT Hyderabad on 18 November 2025, effective 16 December 2025. - Contingent liabilities are dominated by disclosed subsidiary guarantees, and a lease dispute was settled
Clean- Corporate guarantees to lenders for subsidiaries stood at 416.13 crore for a wholly-owned subsidiary and 113.08 crore for a step-down subsidiary as at 31 March 2024. On 20 May 2025, subsidiary Alivira Animal Health Limited agreed to a one-time settlement of its Visakhapatnam leasehold land dispute.
What to watch
- BioForLife Italia acquisition. Completion expected within 3 months of the 8 June 2026 announcement.
- Title deed transfer. Ten freehold land and building properties with net block of 100.38 crore were not individually held in the Company’s name as at 31 March 2026.
- Disputed statutory dues. Ten disputes totalling up to 100 crore were pending across appellate forums as at 31 March 2026.
- Income tax appeal. The appeal against the AY 2018-19 reassessment demand of 3.14 crore, dismissed on 16 September 2025, is before the Income Tax Appellate Tribunal.
Bottom line: This is a disclosed record with unqualified standalone audit opinions, but the disclosure itself tells a story of revenue controls that broke, were flagged, and have not been fully rebuilt. The amalgamation has reset the perimeter, and the goodwill, subsidiary exposures, and loans to related parties all rest on management’s assertion that no impairment or repayment schedule is needed. Watch whether the audit trail is ever turned on, and whether the loans to related parties and the BioForLife Italia deal get firm dates.